Abstract
Recent studies report a possible mortality benefit of treatment with long-acting muscarinic
antagonist (LAMA)/long-acting β2-agonist (LABA)/inhaled corticosteroid (ICS) versus LAMA/LABA combinations in patients with highly symptomatic COPD and a history of exacerbations (≥1 moderate or severe exacerbation in the previous year). We compared the time to all-cause mortality
with LAMA/LABA/ICS versus LAMA+LABA in a population of patients with predominantly moderateto-severe COPD and a predominantly lower exacerbation risk.
antagonist (LAMA)/long-acting β2-agonist (LABA)/inhaled corticosteroid (ICS) versus LAMA/LABA combinations in patients with highly symptomatic COPD and a history of exacerbations (≥1 moderate or severe exacerbation in the previous year). We compared the time to all-cause mortality
with LAMA/LABA/ICS versus LAMA+LABA in a population of patients with predominantly moderateto-severe COPD and a predominantly lower exacerbation risk.
Original language | English |
---|---|
Publication status | Accepted/In press - 17 Mar 2021 |
Event | ATS International Conference Committee: ATS 2021 - Virtual event Duration: 14 May 2021 → 19 May 2021 https://conference.thoracic.org/ |
Conference
Conference | ATS International Conference Committee |
---|---|
Period | 14/05/21 → 19/05/21 |
Internet address |